Clinical Trials

Interventional Drug Clinical Trials

Please click on table and use scroll bars at bottom and right side of table to navigate . Last updated on: 20 March 2025 This list contains only interventional drug trials, for all other type of studies, please refer to clinicaltrials.gov
Type of drugName of drug (Study Name)SponsorPatients who may be eligiblePhaseEnrollment (estimated)Route of administration of study drugLocation of trial sitesTrial identifier ( Click for more information on clinicaltrials.govEmail contact addressStudy Website
1Humanized IgG1 mAb targeting KLRG1+ Tcell Ulviprubart ABC008AbcuroAdults with IBM (Active, NOT RECRUITING) 2/3231SC every 8 weeksINTERNATIONALNCT05721573IBM-201_clinicaltrial@abcuro.com
2Humanized IgG1 mAb targeting KLRG1+ Tcell Ulviprubart ABC008AbcuroAdults with IBM ( Long term extension study; Active, NOT RECRUITING )3270SC every 8 weeksUSA, AUSTRALIANCT06450886IBM-202_clinicaltrial@abcuro.com
3mTOR inhibitorSirolimusUniversity of Kansas Medical Center, USAAdults with IBM (Active, NOT RECRUITING )3140Oral,once dailyUSA, AUSTRALIANCT04789070aheim2@kumc.edu
4Add-on IVIGNanogam® (IVIG)Academisch Medisch Centrum - Universiteit van Amsterdam18 Years to 80 Years (Adult, Older Adult ) with DM/PM/ASyS/IMNM/OM248IVTHE NETHERLANDSNCT05832034Joost Raaphorst, MD, PhD
j.raaphorst@amsterdamumc.nl
5Anti-ILT7HZN-7734 DaxdilimabAmgenAdults with DM and ASyS (Active, NOT RECRUITING )2SC injection weeklyUSA, AUSTRALIANCT05669014clinicaltrials@horizontherapeutics.com
6TYK2 /JAK1 inhibitorBrepocitinib (VALOR)PriovantAdults with DM (Active, NOT RECRUITING )3241Oral,once dailyINTERNATIONALNCT05437263ValorStudyManager@PriovantTx.com https://valorstudy.com/
7TYK2 /JAK1 inhibitorBrepocitinib PriovantAdults with CADM ( Active, NOT RECRUITING )25Oral,once dailyNot availableNCT06433999lindsey.rios@priovanttx.com
matt.cascino@priovanttx.com
8TYK2 inhibitorGLPG3667 (GALARISSO)Galapagos NVAdults with DM262Oral,once dailyINTERNATIONALNCT05695950medicalinfo@glpg.com https://www.glpg.com/innovation/clinical-trials/galarisso/
9TYK inhibitorNintedanib (MINT)Boehringer Ingelheim Adults Myositis Associated Interstitial Lung Disease (MA-ILD) ( Active, NOT RECRUITING )4134Oral,twice dailyUSANCT05799755wes48@pitt.edu https://mint.pitt.edu/
10TLR7/8 inhibitorEmpatoran M5049 (NEPTUNIA)EMD Serono / MerckAdults with DM and PM240Oral,twice dailyINTERNATIONALNCT05650567service@emdgroup.com; eMediUSA@emdserono.com (US only )https://clinicaltrials.merckgroup.com/en/trial-details/?id=MS200569_0041
11JAK 1/2 inhibitorBaricitinib (MYOCIT)Assistance Publique - Hôpitaux de ParisChildren 3-18 years old with new onset JDM216Oral,once dailyFRANCENCT05524311brigitte.bader-meunier@aphp.fr
laure.choupeaux@aphp.fr
12JAK 1/2 inhibitorBaricitinib (BIRD)Assistance Publique - Hôpitaux de ParisAdults with DM362Oral,once dailyFRANCENCT04972760yves.allenbach@aphp.fr
sarra.pochon@aphp.fr
13JAK 1 inhibitorFilgotinibUMC UtrechtAdults with DM260 ( IIM, Behcet's IgG4RD)Oral,once dailyNETHERLANDSNCT06285539a.c.a.marijnissen@umcutrecht.nl
14FcRn inhibitorEfgartigimod PH20 SC (ALKIVIA)ArgenxAdults with IIM (including DM, IMNM, PM, Asys)2/3240SC injection weeklyINTERNATIONALNCT05523167 ClinicalTrials@argenx.com https://myositis-study.com/
15FcRn inhibitorNipocalimab (SPIREA)JanssenAdults with IIM (including DM, IMNM, PM, Asys) (Active, NOT RECRUITING )236IV biweeklyINTERNATIONALNCT05379634Participate-In-This-Study@its.jnj.comhttps://globaltrialfinder.janssen.com/trial/cr109210
16C1s inhibitorRAY-121 (RAINBOW)Chugai; RocheAdults with DM and IMNM1b144(DM, IMNM, ITP, APS, Behcet's, Bullous Pemphigoid, 1 IV infusion ; 2 SC injectionsINTERNATIONALNCT06371417clinical-trials@chugai-pharm.co.jp
17C2 inhibitorEmpasiprubart ARGX-117 (EMPACIFIC)ArgenxAdults with DM242IVUSA NCT06284954clinicaltrials@argenx.com
18C5 inhibitorPozelimab/CemdisiranAustin Neuromuscular CenterAdults with IBM110SC injection monthlyUSA NCT06479863yessar@austinneuromuscle.com
emil@austinneuromuscle.com
19Type 1 IFN alpha and beta blockerAnifrolumab (JASMINE)AstraZenecaAdults with DM and PM3240INTERNATIONALNCT06455449information.center@astrazeneca.comhttps://www.astrazenecaclinicaltrials.com/study/D3463C00003/
20IFN beta blockerDazukibart PF-06823859PfizerAdults with DM and PM3270IV every 4 weeksINTERNATIONALNCT05895786ClinicalTrials.gov_Inquiries@pfizer.com
21IFN beta blockerDazukibart PF-06823859PfizerAdults with DM and PM3/EAP211IV every 4 weeksUS, Bulgaria, ChinaNCT06698796ClinicalTrials.gov_Inquiries@pfizer.com
22Bispecific antibody targeting myeloid cellsDR-0201Sanofi (Dren Bio) Adults with DM and PM ( Not yet recruiting )136 (SLE, CLE, pSS, PM/DM, dcSSc)IVSouth Africa, ANZ, Serbia, Poland, Bulgaria, BosniaNCT06647069clinops@drenbio.com
23GLP-1 receptor agonistPF1801 Froniglutide (FROG)ImmunoforgeAdults with DM and PM239SC injection weeklyKOREANCT05833711mini@immunoforge.com
24Cell Therapy Cell Therapy ADSVFAssistance Publique - Hôpitaux de ParisAdults with IBM132Injection of autologous uncultured adipose-derived stromal vascular fraction (ADSVF)FRANCENCT05032131olivier.benveniste@aphp.fr
25CD19 CAR-T AutologousCABA-201 (RESET-Myositis)Cabaletta Bio6 Years to 75 Years (Child, Adult, Older Adult )1/224infusion of CAR-T following preconditioning with fludarabine and cyclophosphamideUSA /UKNCT06154252clinicaltrials@cabalettabio.com https://www.cabalettabio.com/patients/phase-12-trial-in-myositis
26CD19 CAR-T AutologousRapcabtagene Autoleucel NovartisAdults with myositis 2123Single IV infusion CAR-T or comparatorUSA/ISR/JP/FR/DE/SGNCT06665256novartis.email@novartis.com
27CD19 CAR-T AutologousCC-97540 (Break-free) Juno Therapeutics; BMSAdults with IIM (including DM, IMNM, PM, Asys)1129Infusions of CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab as specifiedUSA/BE/FR/IT/DE/ESNCT05869955Clinical.Trials@bms.comhttps://www.bmsstudyconnect.com/es/en/clinical-trials/NCT05869955.html
28Anti-CD19 CAR-NK allogenicCNTY-101 (CALiPSO-1)Century TherapeuticsAdults with DM, PM, ASyS148 ( SLE, LN, IIM, dcSSc )Lymphodepletion, IV infusion CAR-T, SC injection IL-2USANCT06255028calipso-1_clinicalteam@centurytx.com
29Anti-CD19 CAR-NK allogenicCNTY-101 (CARAMEL)Friedrich-Alexander University Erlangen-Nürnberg (Investigator-initiated study)TBC: SLE, IIM, dcSSc, LN ( not yet recruiting ) 1/2pending infoLymphodepletion, IV infusion CAR-T, SC injection IL-2Germanypending infohttps://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-announces-investigator-initiated-phase-12
30CD19 CAR-T AutologousKYV-101 (CARTIMMUNE)University of Pennsylvania ; KyvernaAdults with IIM (including DM, IMNM, PM ) (Active, NOT RECRUITING )124( PM, DM, IMNM, dcSSc, SLE, AAV)infusion of CAR-T following preconditioning with fludarabine and cyclophosphamideUSANCT06152172Emily.Marcuson@Pennmedicine.upenn.edu
Jacqui.Rick@pennmedicine.upenn.edu
31CD19 CAR-T AutologousKYV 101 Stanford UniversityAdults >25<72 yrs Refractory DM (NOT YET RECRUITING )1b21infusion of CAR-T following preconditioning with fludarabine and cyclophosphamideUSANCT06298019fiorentino@stanford.edu
32CD7 CAR-T AllogenicCD7 CAR T-cellsZhejiang UniversityChild, Adult, Older adult with DM (UNKNOWN STATUS )175 (Crohn's, UC, DM, Still's ) Single IV infusion CAR-T or comparatorCHINANCT05239702huyongxian2000@aliyun.com
hehuangyu@126.com
33CD19 CAR-T Autologousanti-CD19 CAR T cell therapy (CASTLE)University of Erlangen-Nürnberg Medical SchoolAdults with IIM & other autoimmune diseases1/224 (PM, DM, SLE, SScl)Single IV infusion CAR-T GermanyNCT06347718georg.schett@uk-erlangen.de; daniela.bohr@uk-erlangen.de
34CD19 CAR-T Autologousanti-CD19 CAR T cell therapy (CATARSIS)Fondazione Policlinico Universitario Agostino Gemelli IRCCSAdults 18 to 65 yrs old with IIM & other autoimmune diseases ( NOT YET RECRUITING )1/28 (SLE, SSc, DM/PM, and AAV)Lymphodepletion and Single IV infusion CAR-T ItalyNCT06685042mariaantonietta.dagostino@policlinicogemelli.it
35CD19 CAR-T AutologousCT103A (CARTinNS)Tongji HospitalAdults with IIM & other autoimmune diseases136 (NMOSD, MG, CIDP, IIM, MS, AE, MOGAD, POEMS )infusion of CAR-T following preconditioning with fludarabine and cyclophosphamideCHINANCT04561557chuanqin@tjh.tjmu.edu.cn
36CD19 CAR-T AutologousCD19 CAR-T Chongqing Precision Biotech CoAdults with DM & other autoimmune diseases124(SLE, SS, SScl, DM, ANCA Vasculitis )Single IV infusion CAR-T CHINANCT060569211315710223@qq.com
37CD19 CAR-T AutologousRD06-04 Nanjing Bioheng Biotech Adults with IIM & other autoimmune diseases120(SLE, SSc, AAV, IIM, and pSS)Single IV infusion CAR-T CHINANCT06548607peng.yu@bioheng.com
ming.gao@bioheng.com
38CD19 CAR-T AutologousCD19 CAR-T Chongqing Precision Biotech CoChildren with refractory JDM110Lymphodepletion, IV infusion CAR-TCHINANCT06569472meipinglu@zju.edu.cn
39CD19 CAR-T AllogenicAnti-CD19 UCAR-T cellsChongqing Precision Biotech CoChildren with refractory JDM118Lymphodepletion, IV infusion CAR-TCHINANCT06686524meipinglu@zju.edu.cn
40CD19 CAR-T AllogenicUTAA09 PersonGen BioTherapeutics (Suzhou)Adults with IIM & other autoimmune diseases ( NOT YET RECRUITING )110 ( IIM, SLE, SS, SScl, RA, ITP, PBC)Single IV infusion CAR-T CHINANCT06417398njwujian@163.com
41CD19 CAR-T AllogenicRD06-04 Nanjing Bioheng Biotech Adults with IIM & other autoimmune diseases112(SLE, SSc, AAV, IIM, and pSS)Single IV infusion CAR-T CHINANCT06549296peng.yu@bioheng.com
ming.gao@bioheng.com
42CD19 CAR-T AllogenicCD19-CAR-DNT (RJMty19)  RenJi HospitalAdults with IIM & other autoimmune diseases148(SLE, SSc IIM, and ANCA Vas)Single IV infusion CAR-T CHINANCT06316076fuqiong@renji.com
43CD19 CAR-T AllogenicBRL-301Bioray LaboratoriesAdults with IIM & other autoimmune diseases ( BY INVITATION ONLY )N/A15(SLE, SS, SSc, IIM, AAV, Antiphospholipid syndrome )Single IV infusion CAR-T CHINANCT05859997N/A
44CD20 CAR Gamma-Delta (γδ) T AllogeneicADI-001Adicet TherapeuticsAdults with IIM & other autoimmune diseases 1180 (AAV, LN, SLE, SSc, IIM, SPS )Lymphodepletion, IV infusion CAR-TUSANCT06375993clinicaltrials@adicetbio.com
45CD19 BCMA CAR-T AllogenicBAH242Essen BiotechAdults with IIM & other autoimmune diseases 1/275 (AAV, LN, SLE, SS, GP, SSc, IIM, SPS )Lymphodepletion, IV infusion CAR-TCHINANCT06350110clinical-trials@essen-biotech.com
46CD19 CAR-NK AllogenicAnti-CD19 IL-10 CAR-NK Zhejiang UniversityAdults with IIM & other autoimmune diseases N/A15( SS, SSc, IIM, ANCA Vasculitis, Antiphospholipid syndrome )Lymphodepletion then dose-escalated 3 IV infusions CAR-NK CHINANCT06614270jingxue@zju.edu.cn
47CD19 CAR-NK AllogenicNKX019 (Ntrust-2)Nkarta, Inc.Adults with IIM & other autoimmune diseases190 ( SSc, IIM, AAV )Lymphodepletion then dose-escalation 3 infusions CAR-NK USANCT06733935medmonitor@nkartatx.com
Abbreviations

AAV: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis

ASyS: Anti-Synthetase Syndrome

CLE: Cutaneous Lupus Erythematosus

dcSSC: diffuse cutaneous Systemic Sclerosis

DM: Dermatomyositis

EAP: Expanded Access Program

GP: Granulomatous Polyangiitis
JDM: Juvenile Dermatomyositis

FcRn: Neonatal fragment crystallizable receptor

GLP: Glucagon like peptide

JAK: Janus Kinase

KLRG1: Killer cell lectin-like receptor G1

IBM: Inclusion Body Myositis

IFN: Interferon

IIM: Idiopathic Inflammatory Myopathies

ILT: Immunoglobulin like transcript
IMNM: Immune-mediated Necrotising Myopathy
LN: Lupus Nephritis

mAb: monoclonal antibody

MA-ILD: Myositis Associated Interstitial Lung Disease

mTOR: mammalian Target of Rapamycin

PM: Polymyositis

SC: Subcutaneous

SLE: Systemic Lupus Erythematosus

TLR: Toll like receptor

TYK: Tyrosine Kinase